The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology. (1st June 2017)

• Record Type: Journal Article
• Authors: Rozenberg, Serge; Praet, Julie; Pazzaglia, Eliza; Gilles, Christine; Manigart, Yannick; Vandromme, Jean
• Is Part Of: Australian and New Zealand journal of obstetrics and gynaecology. Volume 57:Number 4(2017:Aug.)
• Page Start: 393
• Page End: 399
• Publication Date: 2017-06-01
• Subjects: emergency contraception -- fibroid -- selective progestin receptor modulator -- ulipristal acetate; Obstetrics -- Periodicals; Gynecology -- Periodicals; 618.05
• DOI: 10.1111/ajo.12641
• Languages: English
• ISSNs: 0004-8666

Abstract

Abstract : This review discusses the development of selective progestin receptor modulators (SPRMs) for use in women's health and specifically the use of ulipristal acetate (UPA) as emergency contraception (EC) and as a treatment for symptomatic fibroids in women who want to preserve their fertility or avoid a hysterectomy. As an EC, UPA 30 mg should be recommended for women, within 102 h of unprotected intercourse. As a treatment of fibroids, UPA (5 mg daily dose) should be administered for periods of three months as a pre‐surgical strategy, reducing bleeding and fibroid size and facilitating surgery. A proportion of these patients may even avoid surgery. Future developments will demonstrate whether UPA can be used for other indications such as endometriosis and breast cancer prevention or treatment.